Physician profile
Cameron Pole
NPI 1386090074
$11,351.35
in general payments reported to CMS, 2019-2025
23 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $286 · 2021: $2,107 · 2022: $1,390 · 2023: $3,980 · 2024: $1,324 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,983 · Honoraria: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,982.91 |
| Honoraria | $2,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $3,468.96 | 2021-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $1,900.07 | 2019-2023 | Constellation |
| Eyepoint US, INC. | $1,207.11 | 2021-2023 | |
| Apellis Pharmaceuticals, INC. | $1,007.17 | 2023-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $990.24 | 2020-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $429.74 | 2022-2025 | Vabysmo, Susvimo |
| Biotissue Holdings INC. | $345.74 | 2024 | |
| Bausch & Lomb Americas INC. | $307.31 | 2022-2023 | Xipere |
| Astellas Pharma US INC | $219.02 | 2023-2025 | Izervay |
| Genentech, INC. | $154.44 | 2022-2025 | Vabysmo |
| Biogen, INC. | $144.15 | 2022-2024 | Byooviz |
| Mallinckrodt Hospital Products INC. | $143.26 | 2023-2025 | Acthar |
| Harrow Eye, LLC | $141.85 | 2025 | Iheezo |
| Spark Therapeutics, INC. | $125.00 | 2022 | |
| Allergan, INC. | $125.00 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $123.92 | 2022 | |
| Abbvie INC. | $118.63 | 2025 | |
| Neurotech Pharmaceuticals, INC. | $109.52 | 2025 | |
| Ani Pharmaceuticals, INC. | $73.53 | 2024-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Regeneron Pharmaceuticals, INC. | $61.03 | 2025 | Eylea, Eylea Hd |
| Amgen INC. | $55.84 | 2024-2025 | Pavblu |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $54.25 | 2021 | |
| Coherus Oncology, INC. | $45.57 | 2022-2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Pole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.